RT Journal Article
SR Electronic
T1 Hyperthermia Combined with Chemotherapy for Patients with Residual or Recurrent Oesophageal Cancer After Definitive Chemoradiotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2299
OP 2303
VO 35
IS 4
A1 SHO NISHIMURA
A1 HIROSHI SAEKI
A1 TOMONORI NAKANOKO
A1 YUTA KASAGI
A1 YASUO TSUDA
A1 YOKO ZAITSU
A1 KOJI ANDO
A1 YUICHIRO NAKASHIMA
A1 YU IMAMURA
A1 KIPPEI OHGAKI
A1 EIJI OKI
A1 SAIJI OHGA
A1 KATSUMASA NAKAMURA
A1 MASARU MORITA
A1 YOSHIHIKO MAEHARA
YR 2015
UL http://ar.iiarjournals.org/content/35/4/2299.abstract
AB Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.